“Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis.”
Geoffrey Hinsinger, et al. – Université de Montpellier.
To find CSF biomarkers that are specific to MS, this study found that syndecan-1 (SDC1) serves as a biomarker to distinguish patients with MS from patients with other neurological disorders. While existing fluid biomarkers like NfL are sensitive for detecting MS, they lack specificity – elevated NfL in CSF is a general sign of neurodegeneration that can be due to numerous disorders. Given that clinicians often must discern which neuroinflammatory condition a patient has, as opposed to an “MS or control” binary choice, biomarkers that suffice for these types of comparisons are needed. Levels of SDC1 could robustly identify whether samples were from patients with MS or from those with other neuroinflammatory diseases (p=0.0019, AUC = 0.85). Testing for SDC1 levels may provide clinicians a tool to confirm that the neuroinflammation a patient is experiencing is due to MS.
To view the full paper, see our editor’s commentary, and add your own comments, go to the full paper in the DropCite MS Library.
